summary
Introduced
06/11/2019
06/11/2019
In Committee
06/11/2019
06/11/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A bill to amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes. This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
AI Summary
This bill, the Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act, amends the Medicaid Drug Rebate Program to exclude authorized generic drugs from the calculation of the average manufacturer price (AMP) for brand-name drugs. It also excludes drug manufacturers from the definition of "wholesalers" for the purposes of rebate calculations. These changes aim to provide more accurate pricing information and ensure appropriate Medicaid drug rebates.
Committee Categories
Budget and Finance
Sponsors (6)
Maggie Hassan (D)*,
Ben Cardin (D),
Bill Cassidy (R),
John Cornyn (R),
Debbie Stabenow (D),
Todd Young (R),
Last Action
Read twice and referred to the Committee on Finance. (on 06/11/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/senate-bill/1785/all-info |
| BillText | https://www.congress.gov/116/bills/s1785/BILLS-116s1785is.pdf |
| Bill | https://www.congress.gov/116/bills/s1785/BILLS-116s1785is.pdf.pdf |
Loading...